Oncotelic Therapeutics (OTLC) CEO Vuong Trieu Buys $3.8K of Stock
CEO Vuong Trieu bought 75,000 shares of Oncotelic Therapeutics at $0.05 each.
Reviewed by automated data checks against the source filing. How we make and check alerts
Vuong Trieu, CHAIRMAN AND CEO at Oncotelic Therapeutics, Inc. ($OTLC), bought 75,000 shares at an average price of $0.05, worth about $3,750, on June 23, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $OTLC is down 20.0% after 1 week, down 40.0% after 1 month and down 60.0% to date (from the $0.05 close on Jun 23, 2026).
OTLC
Oncotelic Therapeutics, Inc.
Key Points
- Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, purchased 75,000 shares at $0.05 each on June 23, 2026.
- Shares of OTCQB:OTLC traded near $0.05 on Thursday, with a market cap of approximately $22.2 million.
- No new analyst ratings were reported, and Oncotelic does not currently pay a dividend.
Get $OTLC trade alerts by text
We text you when insiders, Congress or big funds trade $OTLC. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Oncotelic Therapeutics, Inc. alert may contain errors. Disclosures
On June 23, 2026, Vuong Trieu, the Chairman and CEO of Oncotelic Therapeutics, Inc. (OTC Markets OTCQB: OTLC), purchased 75,000 shares of the company at $0.05 each. This transaction was valued at $3,750 and was not part of a pre-planned trading program.
Insider Buying and Selling at Oncotelic Therapeutics, Inc.
In addition to the purchase on June 23, Vuong Trieu made several other transactions recently. On June 24, he bought 115,000 shares at the same price, and on June 22, he acquired 65,000 shares. Earlier, on June 17, he purchased 239,759 shares at $0.04 each. Amit Shah, the CFO, also bought 20,000 shares at $0.05 on June 22.
Oncotelic Therapeutics, Inc. Stock Up 100.0%
Shares of OTCQB:OTLC traded near $0.05 on Thursday. Oncotelic Therapeutics has a market cap of approximately $22.2 million and a P/E ratio of 0.08. The stock's 52-week range is between $0.02 and $0.11, with a 50-day moving average of $0.05 and a 200-day moving average of $0.07. The company has a beta of -0.317, indicating lower volatility compared to the market.
About Oncotelic Therapeutics
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Agoura Hills, California. It focuses on developing drugs for orphan oncology indications. The company is working on several drug candidates, including OT-101 for certain cancers and OXi4503 for acute myeloid leukemia. Led by CEO Dr. Vuong Trieu, the company employs 38 people and aims to target both cancer and viral diseases with its innovative therapies.
Bottom Line
Vuong Trieu's recent share purchases reflect his ongoing support and confidence in Oncotelic Therapeutics. Investors keep a close eye on insider transactions like these for insights into how company leaders view the future. While the stock trades at a low price, its market cap and P/E ratio offer a glimpse into its current valuation. As always, insider buying doesn't necessarily indicate future performance, but it is a data point that many investors find useful.
Related Filing Alerts
Source: Vuong Trieu's Form 4 filing on $OTLC (Jun 23, 2026). Find the original filing: OTLC Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts